Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,662 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Tolerability in Healthy Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, PD and PK Study in Healthy Adults

NCT02211625
View directory record Official record
Conditions
Healthy
Interventions
Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

NCT00981968
View directory record Official record
Conditions
Healthy
Interventions
Sitaxentan sodium/Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891
View directory record Official record
Conditions
Healthy
Interventions
VBY-036
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

NCT01014650
View directory record Official record
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

NCT02575482
View directory record Official record
Conditions
Cognitive Disorders
Interventions
SUVN-D4010, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963
View directory record Official record
Conditions
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Interventions
Progerinin, Placebo
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

NCT03593785
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AZD8233
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

NCT07450521
View directory record Official record
Conditions
Healthy Adult Male
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 2, 2026, 1:04 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

NCT04043338
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XC130-A10H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

NCT03870555
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-954, TAK-954 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine or control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

NCT03844191
View directory record Official record
Conditions
Coronary Disease
Interventions
RUC-4 Compound
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

NCT01989143
View directory record Official record
Conditions
Healthy
Interventions
PF-06480605, Placebo
Drug
Lead sponsor
Telavant, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 2, 2026, 1:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

NCT00827489
View directory record Official record
Conditions
Healthy Subjects
Interventions
HTC-867, Placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Two Formulations of Lamotrigine in Healthy Subjects

NCT00410371
View directory record Official record
Conditions
Mental Disorders
Interventions
Lamotrigine, GI267119
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

NCT07141199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

NCT01477619
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

NCT03301298
View directory record Official record
Conditions
Healthy
Interventions
SXC-2023, Placebo oral capsule
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Anti-MAG First Administration to Human

NCT00622609
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 2, 2026, 1:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728
View directory record Official record
Conditions
Heart Failure, Healthy Volunteer
Interventions
AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

NCT05077865
View directory record Official record
Conditions
Hashimoto Disease
Interventions
MYMD-1, Placebo
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 2, 2026, 1:04 PM EDT